Pharmaceuticals
NUS researchers develop microneedle technology to accelerate diabetic wound healing
'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by ...
2025-03-26 14:21
3416
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutica...
2025-03-26 10:29
3960
CStone to Showcase Five Latest Research Achievements at AACR 2025
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place inChicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific ...
2025-03-26 08:15
3606
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovativein vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP) technolog...
2025-03-25 19:00
2343
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...
2025-03-24 22:45
4771
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...
2025-03-24 22:30
2549
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...
2025-03-24 21:00
2188
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
4714
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...
2025-03-24 20:00
4026
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...
2025-03-24 08:15
3892
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...
2025-03-24 07:56
2983
Syneron Bio Announces Strategic Collaboration with AstraZeneca
BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...
2025-03-21 20:02
3068
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-03-21 08:30
2632
Seegene Unveils HPV Genotyping Solution at EUROGIN 2025
- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held inPortugal from March 16-19 - Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals SEOUL, South K...
2025-03-20 21:00
3075
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing th...
2025-03-20 21:00
3018
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) inChina SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmace...
2025-03-20 20:00
2495
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL * The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmac...
2025-03-20 18:00
2576
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
* Achieved First-Ever Annual Operating Profit * Bottom Line Improved by RMB332.7 Million YoY in 2024 * Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 * Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY * Achieved Fi...
2025-03-20 13:00
4846
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development
CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology ...
2025-03-19 22:00
3625
Jacobio Pharma Announces 2024 Annual Results
BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense ofRMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank b...
2025-03-19 21:42
6824
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
18758
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
16256
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
6745